Status:
COMPLETED
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Colorectal Cancer
Eligibility:
All Genders
Up to 75 years
Phase:
PHASE2
Brief Summary
This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine...
Eligibility Criteria
Inclusion
- adult patients, \<=75 years of age;
- chemotherapy-naive for stage IV colorectal cancer with unresectable liver metastasis;
- \>=1 measurable lesion;
- ECOG status 0-2.
Exclusion
- prior exposure to Avastin;
- clinical or radiological evidence of CNS metastases;
- uncontrolled hypertension, or clinically significant cardiovascular disease;
- ongoing treatment with aspirin (\>325mg/day) or other medications known to predispose to gastrointestinal ulceration.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00700570
Start Date
August 1 2008
End Date
November 1 2011
Last Update
November 2 2016
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung City, Taiwan, 00833
2
Kaohsiung City, Taiwan, 807
3
Taichung, Taiwan, 407
4
Taipei, Taiwan, 00112